# Re-evaluation Task: LUN-001

## Context
- **Case ID**: LUN-001
- **Cancer type**: Non-Small Cell Lung Cancer — Adenocarcinoma
- **Stage**: Stage I
- **Molecular profile**: EGFR exon 19 deletion, PD-L1 TPS >=50%
- **Report file**: experiment_reports\LUN-001_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in LUN-001's research report are the lack of data on Adjuvant Osimertinib (Tagrisso) — Post-Resection and Neoadjuvant Osimertinib (Perioperative Strategy), as these interventions are crucial for understanding the optimal timing and sequence of osimertinib administration in non-small cell lung cancer treatment. Filling these gaps will significantly improve the score by providing more comprehensive insights into the effectiveness of osimertinib in different treatment settings, ultimately informing more personalized and effective treatment strategies for patients with NSCLC.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  14/25  |  56.0% |
| rating_calibration                  |  13/15  |  86.7% |
| clinical_relevance                  |   9/10  |  90.0% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (56.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-001_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Non-Small Cell Lung Cancer — Adenocarcinoma",
    "stage": "Stage I",
    "molecular_profile": [
      "EGFR exon 19 deletion",
      "PD-L1 TPS >=50%"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Surgical Resection (Lobectomy) with Mediastinal Lymph Node Dissection",
      "category": "Standard of Care",
      "composite_rating": 9.6,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Lobectomy is the gold-standard treatment for stage I NSCLC supported by decades of phase 3 RCTs and multiple international guidelines (NCCN, ESMO). JCOG0802 and CALGB 140503 confirmed long-term survival outcomes."
        },
        "survival_benefit": {
          "score": 10,
          "rationale": "5-year overall survival for resected stage IA NSCLC exceeds 90%. JCOG0802 reported 5-year OS of 91.1% with lobectomy and 94.3% with segmentectomy for tumors <=2 cm. Complete surgical resection provides the highest cure rate for stage I disease."
        },
        "accessibility": {
          "score": 10,
          "rationale": "Widely available at all major medical centers worldwide. Standard procedure covered by all insurance plans. Patient is 45 y.o. with ECOG 0 and no comorbidities, making him an ideal surgical candidate."
        },
        "safety_profile": {
          "score": 7,
          "rationale": "Lobectomy carries a 30-day mortality of 1-2% and morbidity of 10-15% including air leak, atrial fibrillation, and pneumonia. VATS/RATS approaches reduce morbidity. Excellent safety in fit patients like this ECOG 0 individual."
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "Surgery is universally applicable regardless of biomarker status. Appropriate for all molecular subtypes in stage I disease. Complete resection enables molecular profiling for adjuvant therapy decisions."
        }
      },
      "mechanism_of_action": "Complete surgical excision of the tumor-bearing lobe with systematic mediastinal lymph node dissection. Removes the primary tumor and regional lymph nodes to achieve R0 resection and accurate pathological staging.",
      "key_evidence": {
        "study_name": "JCOG0802/WJOG4607L",
        "journal": "The Lancet",
        "year": 2022,
        "sample_size": 1106,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0.0,
          "p_value": 0.0
        },
        "pfs_months": {
          "treatment": 0,
          "control": 0
        },
        "orr_percent": {
          "treatment": 0,
          "control": 0
        }
      },
      "biomarker_requirements": [],
      "notable_side_effects": [
        "Post-operative pain",
        "Air leak",
        "Atrial fibrillation",
        "Pneumonia",
        "Reduced pulmonary function",
        "Venous thromboembolism"
      ],
      "availability": "FDA Appro
... (truncated — read full file from experiment_reports\LUN-001_report.json)
```
